What it's for (Indications)
- Loratadine, marketed under various brand names including Conrat, is clinically indicated for the comprehensive relief of symptoms associated with seasonal allergic rhinitis, commonly known as hay fever.
- These symptoms typically include sneezing, rhinorrhea (runny nose), pruritus (itching) of the nose and throat, and ocular pruritus characterized by itchy, watery eyes.
- Furthermore, loratadine is also indicated for the effective management of uncomplicated skin manifestations of chronic idiopathic urticaria, which presents as hives.
- In this context, it provides significant relief from the bothersome itching and aids in reducing both the size and the total number of hives, thereby improving the patient's quality of life.
- The therapeutic benefit extends to both adults and pediatric patients over two years of age, ensuring a broad application for allergic conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and adolescents 6 years of age and older, the recommended oral dosage of loratadine is 10 mg once daily. For pediatric patients aged 2 to 5 years, the recommended oral dosage is 5 mg once daily. In individuals with severe hepatic impairment (Child-Pugh Class C) or chronic renal insufficiency with a glomerular filtration rate (GFR) less than 30 mL/min, a reduced dosage regimen is generally advised. For these patients, an initial dose of 10 mg every other day is recommended to minimize the risk of drug accumulation and potential adverse effects. Liquid formulations are available for pediatric patients or those who have difficulty swallowing tablets. Dosage should not exceed the recommended daily amount to prevent increased incidence of adverse reactions. Adherence to prescribed dosages is crucial for optimal therapeutic outcomes and safety. |
Safety & Warnings
Common Side Effects
- Loratadine is generally well-tolerated, with most reported adverse effects being mild and transient.
- The most commonly observed side effects in adults and children include headache, somnolence (drowsiness), and fatigue.
- Other frequently reported adverse reactions encompass dry mouth, nausea, abdominal pain, and pharyngitis.
- Less common but potentially notable adverse effects can include dizziness, nervousness, wheezing, epistaxis (nosebleed), skin rash, and an increase in appetite.
- Although rare, more serious adverse events such as palpitations, tachycardia, and abnormal liver function have been reported in post-marketing surveillance.
- Given its non-sedating profile compared to first-generation antihistamines, significant central nervous system depression is uncommon; however, individual responses can vary, and patients should be advised regarding potential effects on tasks requiring mental alertness.
Serious Warnings
- Black Box Warning: Loratadine does not carry a formal FDA-mandated Black Box Warning. However, healthcare professionals and patients should be aware of several serious warnings and precautions associated with its use, which are crucial for safe administration. **Serious Warnings:** 1. **Impaired Hepatic and Renal Function:** Caution is advised, and dosage adjustments are necessary in patients with severe liver disease (e.g., Child-Pugh Class C) or significant renal impairment (creatinine clearance < 30 mL/min). Failure to adjust the dose in these populations can lead to increased plasma concentrations of loratadine and its active metabolite, potentially augmenting the risk and severity of adverse effects. 2. **Potential for Drowsiness/Sedation:** While loratadine is classified as a non-sedating antihistamine due to its limited penetration of the blood-brain barrier, a subset of individuals may still experience drowsiness, fatigue, or somnolence. Patients should be advised to exercise caution when engaging in activities requiring mental alertness, such as driving a motor vehicle or operating hazardous machinery, until they ascertain how loratadine affects them. 3. **Drug Interactions:** Concomitant use with medications known to inhibit hepatic metabolism (e.g., ketoconazole, erythromycin, cimetidine) can lead to elevated plasma levels of loratadine and desloratadine, potentially increasing the incidence or intensity of adverse reactions. Although clinically significant cardiac arrhythmias have been rare with loratadine, caution should be exercised, especially in patients with pre-existing cardiac conditions or those on other medications known to affect cardiac rhythm. 4. **Hypersensitivity Reactions:** Although discussed under contraindications, it is imperative to reiterate the risk of hypersensitivity reactions, including severe anaphylaxis, angioedema, and rash. Such reactions necessitate immediate discontinuation of the drug and emergent medical intervention. Patients should be educated on the signs and symptoms of allergic reactions and advised to seek immediate medical attention if they occur. 5. **Not for Acute Asthma:** Loratadine is not effective for and should not be used in the treatment of acute asthma exacerbations or other acute allergic reactions where immediate bronchodilation or systemic corticosteroids are required. It is intended for symptomatic relief of allergic rhinitis and chronic urticaria only. These warnings underscore the importance of individualized patient assessment and careful monitoring during therapy.
- While generally considered safe, loratadine should be administered with caution in specific patient populations.
- Patients with severe hepatic impairment (e.
- g.
- , Child-Pugh Class C) or significant renal impairment (GFR < 30 mL/min) require dosage adjustment, typically to 10 mg every other day, to avoid excessive drug accumulation and increased risk of adverse effects.
- Although loratadine is classified as Pregnancy Category B, indicating no evidence of harm in animal studies, it should be used during pregnancy only if clearly needed after a thorough risk-benefit assessment by a healthcare provider.
- Loratadine and its active metabolite are excreted into breast milk, and therefore caution is advised when administered to nursing mothers.
- Patients should be informed that, despite its non-sedating classification, some individuals may still experience drowsiness or fatigue, which could impair the ability to operate machinery or drive a vehicle safely.
- Concomitant use with drugs that inhibit hepatic metabolism, such as ketoconazole, erythromycin, or cimetidine, may lead to increased plasma concentrations of loratadine and its metabolite, potentially increasing the risk of adverse reactions.
- Patients with phenylketonuria should be aware that certain chewable or orally disintegrating tablet formulations may contain aspartame.
- This medication is not indicated for the treatment of acute asthma exacerbations.
How it Works (Mechanism of Action)
Loratadine exerts its therapeutic effects primarily through its role as a selective, peripheral H1-receptor antagonist. This mechanism involves competitively binding to histamine H1 receptors located on effector cells, such as those found in the gastrointestinal tract, blood vessels, and respiratory tract. By blocking the action of endogenous histamine at these receptors, loratadine effectively inhibits the cascade of symptoms typically associated with allergic reactions, including sneezing, rhinorrhea, pruritus, and urticaria. A key characteristic distinguishing loratadine from older, first-generation antihistamines is its low lipophilicity and high molecular weight, which significantly limit its ability to cross the blood-brain barrier. This restricted passage into the central nervous system accounts for its significantly reduced propensity to induce central nervous system side effects, such as sedation and cognitive impairment. Loratadine is also rapidly and extensively metabolized in the liver, primarily to descarboethoxyloratadine (desloratadine), which is itself an active and potent peripheral H1-receptor antagonist, contributing to the overall antihistaminic effect and extended duration of action.